Katherine Johnson, MD
Family Medicine · Greenwood, SCNPI 1851739676
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,857 of the $80,070 with a category attached, or 82.2%. Corcept Therapeutics accounts for 94.8% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $73,682, more than ten times the $135 reported in 2019. Among family medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $293.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$76K
- Medtronic$2K
- Novo Nordisk$662
- Insulet Corporation$304
- Sequel Med Tech, LLC$241
- Lilly USA, LLC$230
- plus $1K from 22 others
What the payments were for
- Consulting fees$1,4602%
- Speaking & faculty fees$65,85782%
- Travel & lodging$7,3919%
- Food & beverage$4,7096%
- Education$6531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 136 | $75,927 |
| Medtronic(2 entities) | 18 | $1,561 |
| Novo Nordisk | 38 | $662 |
| Insulet Corporation | 8 | $304 |
| Sequel Med Tech, LLC | 7 | $241 |
| Lilly USA, LLC | 12 | $230 |
| Novartis | 9 | $194 |
| Sanofi-aventis U.S. LLC | 5 | $164 |
| Dexcom, Inc. | 5 | $113 |
| Amgen | 4 | $96 |
| Xeris Pharmaceuticals, Inc. | 4 | $87 |
| Bayer | 4 | $72 |
| Tandem Diabetes Care, Inc. | 3 | $67 |
| AstraZeneca | 3 | $47 |
| Cequr Corporation | 2 | $43 |
| BETA Bionics, Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Mannkind Corporation | 1 | $27 |
| Echosens North America, Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Exact Sciences | 1 | $17 |
| AbbVie | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$73,671
- MINIMED 780G$1,213
- Omnipod$156
- TWIIST$145
How this compares
$80,070 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 24 | $778,486 |
| OzempicSemaglutide | 79 | $104,762 |
| MounjaroTirzepatide | 51 | $65,953 |
| TrulicityDulaglutide | 42 | $62,181 |
| JardianceEmpagliflozin | 48 | $51,430 |
| Repatha SureclickEvolocumab | 41 | $27,296 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $23,836 |
| JanuviaSitagliptin Phosphate | 16 | $18,948 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $16,578 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $15,097 |
| KerendiaFinerenone | 11 | $13,306 |
| VascepaIcosapent Ethyl | 15 | $8,710 |
| Victoza 3-PakLiraglutide | 11 | $8,273 |
| Novolog FlexpenInsulin Aspart | 35 | $4,876 |
| HumalogInsulin Lispro | 19 | $4,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $75,927 | $778,48624 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $230 | $132,191112 claims |
| Novo NordiskOzempic | $662 | $104,76279 claims |
| Boehringer IngelheimJardiance | $28 | $51,43048 claims |
| MerckJanuvia | $15 | $18,94816 claims |
| BayerKerendia | $72 | $13,30611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Greenwood
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Jeffrey BroderNorth Augusta$140K
- Terry NagelColumbia$112K
- Scott SmithMount Pleasant$68K
- Jennifer StolinSummerville$59K
- Nicholas PenningsNorth Myrtle Beach$55K
- Nathan AverillMoncks Corner$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.